Clinical Trial Update: Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral Cariprazine [Phase 1, Phase 2]

View source ↗

Summary

The update covers a subcutaneous long-acting cariprazine depot studied in Phase 1/2 for pharmacokinetics, safety, tolerability, and efficacy in adults eligible …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder
• Major Depressive Disorder
• Schizophrenia

Drugs mentioned

• Cariprazine Depot (cariprazine depot)

Snippet

Sponsor: Mapi Pharma Ltd. | Conditions: Major Depressive Disorder (MDD), Bipolar 1 Disorder | Phase 1, Phase 2 | Status: RECRUITING